"For longer-term protection to prevent future outbreaks one could envisage using the combination, the so-called prime / boost approach".
The pathology and cytokine expression data from guinea pigs support the protective potential of α-crystallin based prime boost approach.
Compared to the DNA prime-rAd boost approach previously reported [21], the single-dose rAd strategy reported here has the advantage of a streamlined vaccination protocol.
We show that the prime boost approach based on α-crystallin provides a superior and extended protection against M. tuberculosis infection in guinea pigs.
We evaluated the protective efficacy of a heterologous prime boost approach based on recombinant BCG and DNA vaccines targeting α-crystallin, a prominent latency antigen.
In this study, we evaluated the protective efficacy of a heterologous prime boost approach targeting α-crystallin - a key latency-associated antigen against TB.
Moreover, the DNA prime and viral boost approach has been shown to be important in increasing the breadth of the response repertoire of viral vector vaccines [42], thereby contributing to the overall immunological protection.
If a canarypox prime-recombinant Env protein boost approach indeed offers any unique protective benefit over the other two approaches, it is then necessary to identify new biomarkers other than those included in the current study since none stood out as a unique marker for the success of the HVTN 203 trial vaccine.
Alternatively, either of the two other HIV vaccines evaluated in the current study may have the potential to provide even better protection than the canarypox prime-recombinant Env protein boost approach if the higher responses in certain assays observed only in the HVTN 041 or DP6-001 trial sera are any indication.
Since the same canarypox prime-recombinant Env protein boost approach was used in the recent RV144 trial which showed statistically significant protection against HIV-1 in an efficacy field trial, the results presented in the current report raise several interesting questions.
Since the timing of antigen exposure has been shown to influence the magnitude and quality of the T-cell response, we next analyzed the specific HIV-1 immune responses elicited in mice by NYVAC-B and NYVAC-B-C7L recombinants using a DNA prime/Pox boost approach.
